Single dose of trastuzumab kick starts immune response in certain breast cancers

A tumor's immune response to a single dose of the HER2 inhibitor trastuzumab predicted which patients with HER2-positive breast cancer would respond to the drug on a more long-term basis, according to the results of a new study.